建立一种等位基因特异性 PCR 方法检测感染 C 型人类免疫缺陷病毒 1 型患者的 K65R 耐药突变。
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
机构信息
McGill University AIDS Centre, Department of Medicine, and Lady Davis Institute, Jewish General Hospital, 3755 Cote Ste. Catherine Rd., Montreal, Quebec, Canada H3T 1E2.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):907-11. doi: 10.1128/AAC.01080-09. Epub 2009 Dec 7.
Abstract
The selection of drug-resistant variants of human immunodeficiency virus type 1 (HIV-1) is an impediment to the efficiency of antiretroviral (ARV) therapy. We have developed an allele-specific real-time PCR assay to explore the presence of K65R minority species among treated HIV-1 subtype B and C infections. Thirty HIV-1 subtype C- and 26 subtype B-infected patients lacking K65R as determined by conventional sequencing methods were studied, and viral minority species were found in four HIV-1 subtype C samples.
摘要
人类免疫缺陷病毒 1 型（HIV-1）耐药变异的选择是抗逆转录病毒（ARV）治疗效率的障碍。我们开发了一种等位基因特异性实时 PCR 检测方法，以探索治疗后 HIV-1 亚型 B 和 C 感染中是否存在 K65R 少数种群。通过常规测序方法确定的 30 例 HIV-1 亚型 C 感染和 26 例 HIV-1 亚型 B 感染患者进行了研究，在 4 例 HIV-1 亚型 C 样本中发现了病毒少数种群。
相似文献
1
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 2010 Feb;54(2):907-11. doi: 10.1128/AAC.01080-09. Epub 2009 Dec 7.
2
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
PLoS One. 2013 Aug 21;8(8):e72152. doi: 10.1371/journal.pone.0072152. eCollection 2013.
3
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):253-5. doi: 10.1097/QAI.0b013e318074efd1.
4
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
PLoS One. 2013 Aug 19;8(8):e71972. doi: 10.1371/journal.pone.0071972. eCollection 2013.
5
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
BMC Infect Dis. 2020 Feb 11;20(1):123. doi: 10.1186/s12879-020-4836-z.
6
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Clin Infect Dis. 2009 Jan 15;48(2):239-47. doi: 10.1086/595703.
7
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.
8
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.
9
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):293-6. doi: 10.1097/QAI.0b013e31826a4b34.
10
Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
Antivir Ther. 2011;16(6):925-9. doi: 10.3851/IMP1851.
引用本文的文献
1
Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review.
Indian J Sex Transm Dis AIDS. 2022 Jan-Jun;43(1):13-19. doi: 10.4103/ijstd.ijstd_2_21. Epub 2022 Jun 7.
2
Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.
BMC Cancer. 2020 May 1;20(1):368. doi: 10.1186/s12885-020-06862-w.
3
Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.
Emerg Microbes Infect. 2012 Aug;1(8):e19. doi: 10.1038/emi.2012.15. Epub 2012 Aug 22.
4
Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity.
Nucleic Acids Res. 2015 Jan;43(1):e4. doi: 10.1093/nar/gku1048. Epub 2014 Nov 5.
5
Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.
Curr HIV Res. 2013 Jan;11(1):43-49.
6
Are subtype differences important in HIV drug resistance?
Curr Opin Virol. 2012 Oct;2(5):636-43. doi: 10.1016/j.coviro.2012.08.006. Epub 2012 Sep 21.
7
K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
PLoS One. 2012;7(5):e36549. doi: 10.1371/journal.pone.0036549. Epub 2012 May 16.
8
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.
PLoS One. 2011;6(5):e20208. doi: 10.1371/journal.pone.0020208. Epub 2011 May 31.
本文引用的文献
1
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.
J Infect Dis. 2009 Oct 15;200(8):1202-6. doi: 10.1086/605894.
2
3
The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
AIDS. 2009 Jun 1;23(9):1127-34. doi: 10.1097/QAD.0b013e32832ac34e.
4
Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.
Antimicrob Agents Chemother. 2009 Apr;53(4):1670-2. doi: 10.1128/AAC.01494-08. Epub 2009 Jan 26.
5
Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
Clin Infect Dis. 2009 Feb 15;48(4):476-83. doi: 10.1086/596504.
6
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Clin Infect Dis. 2009 Jan 15;48(2):239-47. doi: 10.1086/595703.
7
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1.
J Virol. 2009 Feb;83(4):2029-33. doi: 10.1128/JVI.01349-08. Epub 2008 Dec 10.
8
HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
AIDS Res Hum Retroviruses. 2008 Nov;24(11):1449-54. doi: 10.1089/aid.2008.0180.
9
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
PLoS Med. 2008 Jul 29;5(7):e158. doi: 10.1371/journal.pmed.0050158.
10
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
J Clin Virol. 2008 Apr;41(4):310-3. doi: 10.1016/j.jcv.2007.12.015. Epub 2008 Mar 7.
Zotero 插件